Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Advanced Pancreatic Acinar Cell Carcinoma
NCT05286827Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in pancreatic acinar cell carcinoma (PACC), sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 1 year. Started Dec 2023; status: terminated.
02
Drugs
olaparib
03
Conditions
pancreatic acinar cell carcinoma (PACC)
Beyond the preview
Go deeper on NCT05286827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286827.